Takeda Seeks E.U. Filings To Offset 2013 Loss Of Blopress Patent
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical expects to file within the next two years for approval in the European Union of its TAK-491 (azilsartan) and Hematide (peginesatide) drugs